INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
01/30/2026
Back to search
Official data from USPTO
E
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
01/31/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
12/15/2016
Registration date
11/13/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/30/2025
Last transaction
01/31/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
GB
Examiner
TURNER, LAUREN
Law office
N50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of patterns of dark and light green dots forming irregular circles, lines, and hexagons, all of which together form the letter "E"; several light green dots appear at random surrounding the "E". The color white represents the background, outlining, shading and/or transparent areas and is not part of the mark.
Holders and representatives
Holders
Evox Therapeutics Limited
Representatives
Susan Piasick Christoff Cooley LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparationsa drug delivery system comprising genetically engineered or purified exosomes for transport of therapeutic agents; pharmaceutical preparationsengineered exosomes that deliver protein for genetic therapy; biological preparations comprising exosome for medical use; biological reagents comprising exosome for medical use; mixed biological preparations comprising exosome for pharmaceutical and medical use; diagnostic reagents comprising exosome for medicinal use in the fields of biologygenetic engineering and pharmaceuticals; pharmaceuticalsmedicinesbiologicsbiotherapeuticsbiosimilars and therapeuticsextracellular vesicle-based nucleic acid therapeutics for the prevention and treatment of infectious diseasescancerdiabetesobesitymetabolic syndromedementiamitochondrial diseaseneuromuscular diseaseinflammatory diseases and autoimmune disorders; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in the detection of infectious diseasescancerdiabetesobesitymetabolic syndromedementiamitochondrial diseaseneuromuscular diseaseinflammatory diseases and autoimmune disorders
Class 42
Scientificmedical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; biological research; clinical research in the field of transformational therapeutics; providing medical and scientific research information in the field of filtration of exosomes from blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of infectious diseases and metabolic disorders; consulting services in the fields of biotechnologypharmaceutical research and development and genetic science
Publications
History of USPTO decisions and trademark events.
41 publications found
C71T
CANCELLED SECTION 71
05/30/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
11/13/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/04/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/30/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/08/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/20/2019
FIMP
FINAL DISPOSITION PROCESSED
02/20/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/13/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
11/13/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/28/2018
PUBO
PUBLISHED FOR OPPOSITION
08/28/2018
GPNX
NOTIFICATION PROCESSED BY IB
08/24/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/08/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/08/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/08/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/18/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/27/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/27/2018
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
06/27/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/15/2018
ATRV
ATTORNEY REVIEW COMPLETED
01/31/2018
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
01/30/2018
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/11/2018
GNFR
FINAL REFUSAL E-MAILED
01/11/2018
CNFR
FINAL REFUSAL WRITTEN
01/11/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/16/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/15/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/15/2017
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
12/15/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/13/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/13/2017
RFNT
REFUSAL PROCESSED BY IB
07/08/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/17/2017
RFRR
REFUSAL PROCESSED BY MPU
06/17/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/10/2017
CNRT
NON-FINAL ACTION WRITTEN
06/09/2017
MAFR
APPLICATION FILING RECEIPT MAILED
06/06/2017
DOCK
ASSIGNED TO EXAMINER
06/02/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/02/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/01/2017
Continuous trademark protection
Get notified about every new filing that threatens E or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.